GIKLY News and Press, Grifols SA Barcelona ADR From 08/21/20

This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...

SAN CLEMENTE, Calif., Aug. 10, 2020 /PRNewswire/ --  ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in ...

SOUTH SAN FRANCISCO, Calif. , July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe , has launched TAVLESSE ® in Germany and the United Kingdom . It was approved by the European Co...

REDMOND, Wash. and NEW YORK , May 26, 2020 /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups ...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Soros Fund Management Holdings ar...

BARCELONA, Spain , May 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that it has received  FDA approval for the Pr...

BARCELONA, Spain , April 28, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a treatment for rabies postexposure prop...

BARCELONA, Spain , April 20, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun iden...

BARCELONA, Spain , April 6, 2020 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 6, 2020 . Grifols' Annual Report on...

BARCELONA, Spain , Feb. 13, 2020 /PRNewswire/ --   Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced that its PharmacyKeeper Verif...